Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
VSV-02 in Lung Cancer: NCT07260591 Clinical Landscape Report 2026
28 September 2026
NCT07260591 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Baricitinib in Job Syndrome: NCT07262983 Clinical Landscape Report 2026
28 September 2026
NCT07262983 clinical landscape for Job Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Memantine hydrochloride in Neuropsychiatric Systemic Lupus Erythematosus: NCT07281105 Clinical Landscape Report 2026
28 September 2026
NCT07281105 clinical landscape for Neuropsychiatric Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and developme…
9 min read
Cenerimod in Systemic Lupus Erythematosus: NCT07266090 Clinical Landscape Report 2026
28 September 2026
NCT07266090 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dual-targeting BCMA/CD19 CAR-T(Ucello Therapeutics) in Systemic Lupus Erythematosus: NCT07274059 Clinical Landscape Report 2026
28 September 2026
NCT07274059 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LY-4298445 in Rheumatoid Arthritis: NCT07276958 Clinical Landscape Report 2026
28 September 2026
NCT07276958 clinical landscape for Rheumatoid Arthritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SYS-6090 in Urologic Neoplasms: NCT07280832 Clinical Landscape Report 2026
28 September 2026
NCT07280832 clinical landscape for Urologic Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IDE-397 in Pancreatic adenocarcinoma: NCT07277413 Clinical Landscape Report 2026
28 September 2026
NCT07277413 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tebentafusp in Uveal Melanoma: NCT07276386 Clinical Landscape Report 2026
28 September 2026
NCT07276386 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Muscle Invasive Bladder Urothelial Carcinoma: NCT07279597 Clinical Landscape Report 2026
28 September 2026
NCT07279597 clinical landscape for Muscle Invasive Bladder Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Pafolacianine in Endometrial Carcinoma: NCT07278986 Clinical Landscape Report 2026
28 September 2026
NCT07278986 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19/BCMA CAR-NK Cells(The Children's Hospital of Zhejiang University School of Medicine) in Scleroderma: NCT07283315 Clinical Landscape Report 2026
28 September 2026
NCT07283315 clinical landscape for Scleroderma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.